Aberrant adrenal sensitivity to multiple ligands in unilateral incidentaloma with subclinical autonomous cortisol hypersecretion: a prospective clinical study.
BACKGROUND
Incidentally discovered adrenal tumours are frequently associated with subclinical autonomous cortisol hypersecretion of unknown origin. Aberrant hormone receptors have been observed in case reports of overt Cushing's syndrome. The question arises as to whether such receptors may be present in the functioning adrenal incidentaloma, which is common and might be a subclinical stage of Cushing's syndrome.


METHODS
Twenty-one consecutive patients with a unilateral incidentaloma, the biochemical features of subclinical cortisol hypersecretion and/or the scintigraphic features of an autonomously functioning adrenal adenoma were investigated for plasma cortisol responses to various stimuli: upright posture, meal, combined hypothalamic-hormones, the vasopressin analogue terlipressin, glucagon, angiotensin II, the serotonin 5-HT4 agonist cisapride, and ACTH. Six normal controls were similarly investigated. All subjects were studied during 8 mg per day dexamethasone in order to avoid any ACTH-dependent variation of plasma cortisol.


RESULTS
The most constant responses in adrenal incidentalomas were observed after stimulation by terlipressin (18/20 patients, 28-415% cortisol increase) and cisapride (17/21 patients, 25-364% cortisol increase). Eighteen out of 21 patients responded to several stimuli (cortisol increase >or= 25%), and all responded to at least one stimulus other than ACTH, while such responses were absent in the controls. Plasma ACTH remained suppressed in all subjects throughout the study.


CONCLUSIONS
Aberrant membrane receptors detected by in vivo stimulation tests appear to be common in autonomously functioning unilateral adrenocortical adenomas. These receptors may be involved in the modulation of cortisol secretion in adrenal incidentaloma, with potential therapeutic consequences for the control of subclinical cortisol hypersecretion.
Reznik
Y
Y
Department of Endocrinology, CHU of Caen, Caen, France. reznik-y@chu-caen.fr
Lefebvre
H
H
Rohmer
V
V
Charbonnel
B
B
Tabarin
A
A
Rodien
P
P
Lecomte
P
P
Bardet
S
S
Coffin
C
C
Mahoudeau
J
J
D000236:Adenoma / Q000097:blood / Q000378:metabolism*; D000310:Adrenal Gland Neoplasms / Q000097:blood / Q000378:metabolism*; D000324:Adrenocorticotropic Hormone / Q000097:blood; D000328:Adult; D000368:Aged; D000804:Angiotensin II / Q000008:administration & dosage; D016022:Case-Control Studies; D020117:Cisapride / Q000008:administration & dosage; D004435:Eating; D005260:Female; D005934:Glucagon / Q000008:administration & dosage; D006801:Humans; D006854:Hydrocortisone / Q000097:blood / Q000378:metabolism*; D007028:Hypothalamic Hormones / Q000008:administration & dosage; D033162:Incidental Findings; D008236:Lypressin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D008297:Male; D008875:Middle Aged; D011187:Posture; D011446:Prospective Studies; D017366:Serotonin Receptor Agonists / Q000008:administration & dosage; D013268:Stimulation, Chemical; D000077585:Terlipressin; D014662:Vasoconstrictor Agents / Q000008:administration & dosage
D007028:Hypothalamic Hormones; D017366:Serotonin Receptor Agonists; D014662:Vasoconstrictor Agents; D000804:Angiotensin II; D008236:Lypressin; D000077585:Terlipressin; D000324:Adrenocorticotropic Hormone; D005934:Glucagon; D020117:Cisapride; D006854:Hydrocortisone